ReNeuron Group (LON:RQE) introduced its exosome nanomedicine programme at its recent capital markets day. While being a preclinical programme, it has three significant advantages. First, it gives ReNeuron the potential to expand into new therapeutic indications. Second, it opens up the potential for collaborations in diagnostics and drug delivery. Third, it builds on its wealth of experience and IP and on its CTX cell line on which ReNeuron’s existing products and the exosome platform are built.
A new (existing) platform emerges
ReNeuron’s capital markets day showcased its exosome nanomedicine platform. ReNeuron’s scientists, clinicians and its collaborators described the origin and functions of these naturally occurring sub-cellular vesicles. ReNeuron has been working on exosomes for many years since discovering them as a by-product of its genetically modified human neural stem cell line (CTX). The expert panel also described the potential use and applications of exosomes.
To read the entire report Please click on the pdf File Below: